Effects of sphingomyelin on aberrant colonic crypt foci development, colon crypt cell proliferation and immune function in an aging rat tumor model

Food and Chemical Toxicology

Volumn 41, Issue 4, 2003, Pages 471-476

  Exon, J H ^a   South, E H ^a  

^a UNIVERSITY OF IDAHO   (United States)

Author keywords

Aberrant crypt foci; Antibody response; Delayed type hypersensitivity; Immune response; Natural killer cell; Preneoplastic lesions; Sphingomyelin

Indexed keywords

AZOXYMETHANE; SPHINGOMYELIN;

AGING; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; CELL ACTIVITY; CELL PROLIFERATION; COLON INJURY; CONTROLLED STUDY; CRYPT CELL; DELAYED HYPERSENSITIVITY; DIET; DRUG EFFECT; IMMUNE RESPONSE; MALE; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NONHUMAN; PRECANCER; RAT;

AGING; ANIMALS; AZOXYMETHANE; BODY WEIGHT; CARCINOGENS; CELL DIVISION; COLON; COLONIC NEOPLASMS; HEMOCYANIN; HYPERSENSITIVITY, DELAYED; IMMUNITY; IMMUNOGLOBULIN G; KILLER CELLS, NATURAL; MALE; PRECANCEROUS CONDITIONS; RATS; RATS, SPRAGUE-DAWLEY; SPHINGOMYELINS; SPLEEN;

EID: 0037400136     PISSN: 02786915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0278-6915(02)00297-1     Document Type: Article

References (28)

1. Aggarwal B.B., Higuchi M. Role of ceramide in tumour necrosis-factor-mediated apoptosis and nuclear factor-κb activation. Biochemical Society Transactions: The Cell Biology of Lipid Signaling. 25:1997;1166-1171.
2. Bird R.P. Role of aberrant crypt foci in understanding the pathogenesis of colon cancer. Cancer Letters. 93:1995;55-71.
3. Cheng P.C., Dykstra M.L., Mitchell R.N., Pierce S.K. A role for lipid rafts in B cell antigen receptor signaling and antigen targeting. Journal of Experimental Medicine. 190:1999;1549-1560.
4. Dillehay D.L., Webb S.K., Schmelz E.-M., Merrill A.H. Jr. Dietary sphingomyelin inhibits 1,2-dimethylhydrazine-induced colon cancer in CL1 mice. Journal of Nutrition. 124:1994;615-620.
5. Exon J.H., Bussiere J.L., Mather G.G. Immunotoxicity testing in the rat. an improved multiple assay model International Journal of Immunopharmacology. 12:1990;699-701.
6. Exon J.H., Koller L.D., Talcott P.A., O'Reilly C.A., Henningsen G.M. Immunotoxicity testing. an economical multiple-assay approach Fundamental and Applied Toxicology. 7:1986;387-397.
7. Hannun Y.A. The sphingomyelin cycle and the second messenger function of ceramide. Journal of Biological Chemistry. 269(5):1994;3125-3128.
8. Hannun Y.A., Linardic C.M. Sphingolipid breakdown products. anti-proliferative and tumor-suppressor lipids Biochimica et Biophysica Acta. 1154:1993;223-236.
9. Hannun Y.A., Loomis C.R., Merrill A.H., Bell R.M. Sphingosine inhibition of protein kinase C activity and of phorbol dibutyrate binding in vitro and in human platelets. Journal of Biological Chemistry. 261(27):1986;1204-1209.
10. Jayadev S., Liu B., Bielawaka A.E., Lee J.Y., Nazaire F., Yu M., Obeid L.M., Hannun Y.A. Role for ceramide in cell cycle arrest. Journal of Biological Chemistry. 270:1995;2047-2052.
11. Lepple-Wienhues A., Belka C., Laun T., Jekle A., Walter B., Wieland U., Welz M., Heil L., Kun J., Busch G., Weller M., Bamberg M., Gulbins E., Lang F. Stimulation of cd95 (fas) blocks t lymphocyte calcium channels through sphingomyelinase and sphingolipids. Proceedings of the National Academy of Sciences of the U.S.A. 96:1999;13795-13800.
12. McCallion K., Mitchell R.M.S., Wilson R.H., Kee F., Watson R.C.P., Collins J.S.A., Gardiner K.R. Flexible sigmoidscopy and the changing distribution of colorectal cancer. implications for screening Gut. 48:2001;522-525.
13. McLellan E.A., Bird R.P. Aberrant crypts. potential preneoplastic lesion in the murine colon Cancer Research. 48:1988;6187-6192.
14. McLellan E.A., Medline A., Bird R.P. Sequential analyses of the growth and morphological characteristics of aberrant crypt foci. Putative preneoplastic lesions Cancer Research. 51:1991;5270-5274.
15. McMahon T., Peggins J., Centra M.M., Weiner M. Age-related changes in biotransformation of azoxymethane and methylazoxymethanol in vitro. Xenobiotica. 20:1990;501-513.
16. Magnuson B.A., South E.H., Exon J.H., Dashwood R.H., Xu M., Hendrix K., Hubele S. Increased susceptibility of adult rats to azoxymethane-induced aberrant crypt foci. Cancer Letters. 161:2000;185-193.
17. Martinova E.A. Influence of sphingolipids on T lymphocyte activation. Biochemistry (Mosc). 63(1):1998;102-110.
18. Mathias S., Younes A., Kan C.-C., Orlow I., Joseph C., Kolesnick R.N. Activation of the sphingomyelin signaling pathway in intact EL4 cells and in a cell-free system by IL-1beta. Science. 259:1993;519-522.
19. Merrill A.H., Schmelz E.M., Wang E., Dillehay D.L., Rive L.G., Meredith F., Riley R.T. Importance of sphingolipids and inhibitors of sphingolipid metabolism as components of animal diets. Journal of Nutrition. 127:1997;830. S-833S.
20. Nucci M.R., Robinson C.R., Longo R., Campbell P., Hamilton S.R. Phenotypic and genotypic characteristics of aberrant crypt foci in human colorectal mucosa. Human Pathology. 28:1997;1396-1407.
21. Ohanian J., Ohanian V. Sphingolipids in mammalian cell signalling. Cellular and Molecular Life Sciences. 58:2001;2053-2068.
22. Pahlavani M.A., Richardson A. The effect of age on the expression of interleukin-2. Mechanisms of Ageing and Development. 89:1996;125-154.
23. Pahlavani M., Vargas D.M. The effect of a ceramide analog, n-acetylsphingosine on the induction of proliferation and IL-2 synthesis in T cells from young and old F344 rats. Immunopharmacology. 49:2000;343-354.
24. Schmelz E.M., Dillehay D.L., Webb S.K., Reiter A., Adams J., Merrill A.H. Sphingomyelin consumption suppresses aberrant colonic crypt foci and increases the proportion of adenomas versus adenocarcinomas in CF1 mice treated with 1,2-dimethylhydrazine. implications for dietary sphingolipids and colon carcinogenesis Cancer Research. 56:1996;4936-4941.
25. Schmelz E.M., Sullards M.C., Dillehay D.L., Merrill A.H. Jr. Colonic cell proliferation and aberrant crypt foci formation are inhibited by dairy glycosphingolipids in 1,2-dimethylhydrazine-treated C11 mice. Journal of Nutrition. 130:2000;522-527.
26. Sweeney E.A., Inokuchi J., Igarashi Y. Inhibition of sphingolipid induced apoptosis by caspase inhibitors indicates that sphingosine acts in an earlier part of the apoptotic pathway than ceramide. FEBS Letters. 425:1998;61-65.
27. Takayama T., Katsuki S., Takahashi Y., Ohi M., Nojiri S., Sakamaki S., Kato J., Kogawa K., Miyake H., Niitsu Y. Aberrant crypt foci of the colon as precursors of adenoma and cancer. New England Journal of Medicine. 339:1998;1277-1284.
28. Yamada K., Yoshitake K., Sato M., Ahnen D.J. Proliferating cell nuclear antigen expression in normal, preneoplastic, and neoplastic colonic epithelium. Gastroenterology. 103:1992;160-197.